Global Myelofibrosis Pipeline Insight Research Report 2021: Comprehensive Insights of on Approx 55+ Companies and 55+ Pipeline Drugs – ResearchAndMarkets.com
DUBLIN–(BUSINESS WIRE)–The “Myelofibrosis – Pipeline Insight, 2021” drug pipelines has been added to ResearchAndMarkets.com’s offering.
This “Myelofibrosis – Pipeline Insight, 2021,” report provides comprehensive insights about 55+ companies and 55+ pipeline drugs in Myelofibrosis pipeline landscape.
It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Report Highlights
The companies and academics are working to assess challenges and seek opportunities that could influence Myelofibrosis R&D. The therapies under development are focused on novel approaches to treat/improve Myelofibrosis.
Myelofibrosis Emerging Drugs Chapters
This segment of the Myelofibrosis report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Myelofibrosis Emerging Drugs
Parsaclisib: Incyte Corporation
Parsaclisib (INCB050465) is a potent and selective next-generation PI3K inhibitor that differs in structure from first-generation PI3K inhibitors. The drug is in Phase III clinical evaluation for the treatment of Myelofibrosis.
Selinexor: Karyopharm Therapeutics
Selinexor is an orally administered, small molecule, inhibitor of chromosome region maintenance 1 protein (CRM1). It functions by binding with, and inhibiting, the nuclear export protein, XPO1, leading to the accumulation of tumor suppressor proteins in the cell nucleus. Selinexor, (XPOVIO), has been approved by the USFDA for relapsed or refractory multiple myeloma, relapsed or refractory diffuse large B-cell lymphoma (DLBCL), and in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least one prior therapy.
Selinexor is also currently being evaluated in ongoing Phase 2 and 3 clinical studies in patients with a variety of hematologic and solid tumor malignancies. The drug is in Phase II clinical studies for the treatment of Myelofibrosis.
Myelofibrosis: Therapeutic Assessment
This segment of the report provides insights about the different Myelofibrosis drugs segregated based on following parameters that define the scope of the report, such as:
Major Players in Myelofibrosis
There are approx. 55+ key companies which are developing the therapies for Myelofibrosis. The companies which have their Myelofibrosis drug candidates in the most advanced stage, i.e. Phase III include, Incyte Corporation.
Phases
This report covers around 55+ products under different phases of clinical development like
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
Myelofibrosis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
- Oral
- Parenteral
- Intravitreal
- Subretinal
- Topical
- Molecule Type
Products have been categorized under various Molecule types such as
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Gene therapy
- Product Type
The drugs have been categorized under various product types like Mono, Combination and Mono/Combination.
Myelofibrosis: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Myelofibrosis therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Myelofibrosis drugs.
Myelofibrosis Report Insights
- Myelofibrosis Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
Myelofibrosis Report Assessment
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Key Questions Answered
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Myelofibrosis drugs?
- How many Myelofibrosis drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Myelofibrosis?
- What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Myelofibrosis therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Myelofibrosis and their status?
- What are the key designations that have been granted to the emerging drugs?
Key Players
- Incyte Corporation
- Karyopharm Therapeutics
- Celgene Corporation
- PharmaEssentia
- Novartis
- Secura Bio
- Pharmaxis
- Novartis Oncology
- AstraZeneca
- Cellenkos
- Jacobio Pharmaceuticals
- Ohm oncology
Key Products
- Parsaclisib
- Selinexor
- Lenalidomide
- Ropeginterferonum alfa-2b
- Panobinostat
- PXS-5505
- Spartalizumab
- Selumetinib
- CK-0804
- JAB-8263
- OHM-581
For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/8581kn
Contacts
ResearchAndMarkets.com
Laura Wood, Senior Press Manager
[email protected]
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
